Evolution of the Average Target: Edwards Lifesciences Corporation

Evolution of the Target Price: Edwards Lifesciences Corporation

Changes in Analyst Recommendations: Edwards Lifesciences Corporation

32e2e72f941b9d3666dc0852c9e57f00.Pw8uOVYA67xHPqfgHtR8ZZHYn9Ss-dr4y5n4A4WFiyg.SGVvUG902_BwTcy_Kpg6NqWbxrHttYu9ks6zU-P18kZmNx9dMEud1wt38g~fd77cdb394cb098b8915f6b39d01aa21
08-21 Argus Adjusts Price Target on Edwards Lifesciences to $115 From $105, Maintains Buy Rating MT
07-28 UBS Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $110 From $90 MT
07-27 Rothschild & Co Redburn Adjusts Edwards Lifesciences Price Target to $102 From $99, Maintains Buy Rating MT
07-24 Edwards Lifesciences Seen Building on Catalyst Pipeline, RBC Says MT
07-24 Deutsche Bank Adjusts Edwards Lifesciences Price Target to $103 From $100, Maintains Buy Rating MT
07-24 Raymond James Adjusts Price Target on Edwards Lifesciences to $103 From $100, Maintains Outperform Rating MT
07-24 Piper Sandler Adjusts Price Target on Edwards Lifesciences to $101 From $100, Maintains Overweight Rating MT
07-24 Jefferies Adjusts Price Target on Edwards Lifesciences to $105 From $102, Maintains Buy Rating MT
07-24 Bernstein Adjusts Price Target on Edwards Lifesciences to $99 From $96, Maintains Market Perform Rating MT
07-24 Leerink Partners Upgrades Edwards Lifesciences to Outperform From Market Perform, Adjusts PT to $101 From $87 MT
07-16 Truist Adjusts Price Target on Edwards Lifesciences to $95 From $90, Maintains Hold Rating MT
07-15 Mizuho Adjusts Price Target on Edwards Lifesciences to $105 From $100, Maintains Outperform Rating MT
07-14 Baird Adjusts Price Target on Edwards Lifesciences to $94 From $87, Maintains Neutral Rating MT
07-14 Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $102 From $98, Maintains Buy Rating MT
07-13 RBC Raises Price Target on Edwards Lifesciences to $110 From $100, Keeps Outperform Rating MT
07-08 Citigroup Adjusts Edwards Lifesciences Price Target to $110 From $101 MT
07-06 Evercore ISI Adjusts Price Target on Edwards Lifesciences to $100 From $93 MT
06-30 BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating MT
06-29 Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says MT
06-16 Edwards Lifesciences Seen Benefiting From CMS Transcatheter Aortic Valve Replacement Rule, RBC Says MT
06-11 Edwards Lifesciences Set to Benefit from TAVR Coverage Update, RBC Says MT
06-02 TD Cowen Adjusts Price Target on Edwards Lifesciences to $104 From $97, Maintains Buy Rating MT
04-28 Rothschild & Co Redburn Adjusts Price Target on Edwards Lifesciences to $99 From $94, Maintains Buy Rating MT
04-24 Mizuho Securities Adjusts Edwards Lifesciences Price Target to $100 From $95, Maintains Outperform Rating MT
04-24 Truist Securities Adjusts Price Target on Edwards Lifesciences to $90 From $89, Maintains Hold Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+12.3%
+3.96%
+10.32%
+30.35%
+31.15%
+16.72%
+16.3%
+7.64%
-8.52%
+7.78%
Average +12.80%
Weighted average by Cap. +13.31%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
89.90USD
Average target price
100.96USD
Spread / Average Target
+12.30%
High Price Target
110.00USD
Spread / Highest target
+22.36%
Low Price Target
84.00USD
Spread / Lowest Target
-6.56%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EW Stock
  4. Consensus Edwards Lifesciences Corporation
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!